EQUINE HERPESVIRUS TYPE 5 IN BRONCHOALVEOLAR LAVAGE FLUID OF HORSES WITH EQUINE MULTINODULAR PULMONARY FIBROSIS (EMPF) AND WITH OTHER CHRONIC RESPIRATORY DISORDERS.

The aim of the study was to estimate the prevalence and the potential role of equine herpesvirus type 5 (EHV-5) in the bronchoalveolar lavage fluid (BALF) samples of horses with chronic respiratory signs. Altogether 60 horses with chronic respiratory signs of minimum of 2 weeks duration were involved in the study. Horses were clinically examined, respiratory endoscopy, thoracic radiography, ultrasonography, tracheal culture and evaluation of BALF cytology was performed. EHV-5 PCR assay was carried out on BALF samples of 15 horses in a commercial laboratory (IDEXX-VetMedLab Germany), 54 BALF samples were tested in the research laboratory of Szent Istvan University, Faculty of Veterinary Science and samples of 9 horses were tested by both laboratories. PCR testing by the two different laboratories gave homogenous results. Altogether there were 7 horses (prevalence: 11,6%) with positive PCR results. Three of them were diagnosed with EMPF based on histologic results of lung biopsy specimens or post-mortem tissue samples. These three horses were genetically closely related warmbloods. Two other horses suffered of suspected EMPF based on thoracic radiograpy with nodular interstitial pattern, EHV-5 positivity and intranuclear inclusion bodies but pulmonary biopsy was not performed on any of them. One positive horse was diagnosed with inflammatory airway disease and one with systemic granulomatous disease. Presence of EHV- 5 in BALF significantly (Fisher test, p < 0,001) correlated with the diagnosis of EMPF. BALF testing for EHV-5 is an important examination when establishing the diagnosis of EMPF. Genetic predisposition might render the patient more susceptible to EMPF or viral infection

Hypoalbuminemia affects one third of acute pancreatitis patients and is independently associated with severity and mortality

The incidence and medical costs of acute pancreatitis (AP) are on the rise, and severe cases still have a 30% mortality rate. We aimed to evaluate hypoalbuminemia as a risk factor and the prognostic value of human serum albumin in AP. Data from 2461 patients were extracted from the international, prospective, multicentre AP registry operated by the Hungarian Pancreatic Study Group. Data from patients with albumin measurement in the first 48 h (n = 1149) and anytime during hospitalization (n = 1272) were analysed. Multivariate binary logistic regression and Receiver Operator Characteristic curve analysis were used. The prevalence of hypoalbuminemia (< 35 g/L) was 19% on admission and 35.7% during hospitalization. Hypoalbuminemia dose-dependently increased the risk of severity, mortality, local complications and organ failure and is associated with longer hospital stay. The predictive value of hypoalbuminemia on admission was poor for severity and mortality. Severe hypoalbuminemia (< 25 g/L) represented an independent risk factor for severity (OR 48.761; CI 25.276-98.908) and mortality (OR 16.83; CI 8.32-35.13). Albumin loss during AP was strongly associated with severity (p < 0.001) and mortality (p = 0.002). Hypoalbuminemia represents an independent risk factor for severity and mortality in AP, and it shows a dose-dependent relationship with local complications, organ failure and length of stay.Peer reviewe

High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial

Introduction Acute pancreatitis (AP) is an inflammatory disease with no specific treatment. Mitochondrial injury followed by ATP depletion in both acinar and ductal cells is a recently discovered early event in its pathogenesis. Importantly, preclinical research has shown that intracellular ATP delivery restores the physiological function of the cells and protects from cell injury, suggesting that restoration of energy levels in the pancreas is therapeutically beneficial. Despite several high quality experimental observations in this area, no randomised trials have been conducted to date to address the requirements for energy intake in the early phase of AP. Methods/design This is a randomised controlled two-arm double-blind multicentre trial. Patients with AP will be randomly assigned to groups A (30 kcal/kg/day energy administration starting within 24 hours of hospital admission) or B (low energy administration during the first 72 hours of hospital admission). Energy will be delivered by nasoenteric tube feeding with additional intravenous glucose supplementation or total parenteral nutrition if necessary. A combination of multiorgan failure for more than 48 hours and mortality is defined as the primary endpoint, whereas several secondary endpoints such as length of hospitalisation or pain will be determined to elucidate more detailed differences between the groups. The general feasibility, safety and quality checks required for high quality evidence will be adhered to. Ethics and dissemination The study has been approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (55961-2/2016/EKU). This study will provide evidence as to whether early high energy nutritional support is beneficial in the clinical management of AP. The results of this trial will be published in an open access way and disseminated among medical doctors

Mobileszköz-alapú gyermekkori látásszűrés a tompalátás korai felismerésére

Bevezetés: Az amblyopia vagy tompalátás binokuláris eredetű fejlődési zavar, amelyet a legtöbbször egy szemet érintő, lencsével nem korrigálható látásromlásként definiálnak. Magas prevalenciájával világszerte népegészségügyi problémát jelent, így a kisgyermekkori látásszűrések fontos célja az amblyopia megelőzése. Célkitűzés: Célunk egy mobilapplikáció-alapú térlátásvizsgáló teszt (EuvisionTab ® sztereoteszt, ETS) értékelése, mellyel a tompalátás és rizikófaktorai (kancsalság, törési hibák) időben kiszűrhetők. Módszer: Vizsgálataink során nemzetközileg ismert klinikai sztereoteszteket (Lang II, TNO, Stereo Fly, Frisby) hasonlítottunk össze az EuvisionTab sztereoteszt különböző verzióival gyermekek körében (n = 453, átlagéletkor: 7,45 év). A random pontokból álló EuvisionTab sztereoteszt esetén 4 különböző beállítást alkalmaztunk, a dinamizmust, a pontsűrűséget (denzitást), illetve a vizuális zajt változtatva. A tesztek hatékonyságát ’receiver-operating characteristic’ (ROC) módszerrel értékeltük, melynek legfontosabb mérőszáma a görbe alatti terület (AUC). Eredmények: Az EuvisionTab sztereotesztek nagy szenzitivitásúnak bizonyultak a klasszikus klinikai tesztekhez viszonyítva, specificitásuk viszont több esetben elmaradt tőlük. Az amblyopia esetében a legjobb szenzitivitást (91%) a kis denzitású, vizuális zajt tartalmazó dinamikus teszt érte el, míg a legjobb specificitásértéket (89%) a statikus nagy denzitású esetében kaptuk. A hagyományos klinikai tesztek közül a legjobb szenzitivitással (88%) a TNO rendelkezett, míg a legjobb specificitással (98%) a Lang-teszt. A ROC-analízis alapján minden alkalmazott sztereoteszt jó vagy kiválóan alkalmas (ROC-AUC>0,80) az amblyopia szűrésére, míg a kancsalság esetén a TNO, a Stereo Fly, valamint az EuvisionTab tesztek feleltek meg ennek a kritériumnak. Következtetés: Az EuvisionTab sztereotesztek megfelelőnek bizonyultak az amblyopia szűrésére, nagy szenzitivitással rendelkeznek. A módszer további előnyei a véletlenszerű ingersorozat, a rugalmas paraméterbeállítások, a statisztikai alapú döntéshozatal, a kényelmes dokumentáció, valamint a könnyű és gyors kivitelezhetőség. Ezek alapján a legmodernebb látásszűrési protokoll részévé válhat. Orv Hetil. 2024; 165(16): 620–628

Diagnostic value of [Tc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer

Background: A large number of studies have proved that prostate-specific membrane antigen-positron emission tomography/computer tomography (PSMA-PET/CT) provides excellent accuracy in primary staging and restaging of prostate cancer. Less data exist with PSMA-single photon emission computed tomography (SPECT)/CT investigations. Objective: The aim of this study was to evaluate the performance of [ 99m Tc]Tc-PSMA-I&S (for imaging and surgery) in prostate cancer. Design and methods: We retrospectively analysed PSMA-SPECT/CT scans of 20 healthy volunteers and 100 male patients with prostate cancer. All of them had histologically confirmed prostate cancer. In all, 28 patients were examined for primary staging and 72 for biochemical recurrence or progressive disease. Whole body SPECT/CT imaging was carried out 6 h after the intravenous administration of 666 ± 102 MBq [ 99m Tc]Tc-PSMA-I&S. Images were evaluated visually and semi-quantitatively. Results: Patient-based sensitivity, specificity, positive predictive value, negative predictive value and accuracy for primary prostate cancer were 86%, 100%, 100%, 83% and 92%, respectively. For detecting metastases in primary staging, these values were 88%, 100%, 100%, 85% and 93%, respectively. The radiopharmaceutical uptake of primary prostate cancer was significantly higher than in normal prostate. The patient-based sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the method in the visualization of local recurrence were 67%, 100%, 100%, 86% and 89%, and for detecting metastases in restaging were 91%, 92%, 98%, 75% and 91%, respectively. In restaging, detection rates were 37% under prostate-specific antigen level of 1 ng/mL, 74% between 1 and 5 ng/mL and 80% >5 ng/mL. Conclusion: [ 99m Tc]Tc-PSMA-I&S-SPECT/CT can be easily integrated into the routine diagnostic practice, and it provides usable data in primary staging and restaging of prostate cancer. Quantitative assessment of PSMA-SPECT/CT has the potential to be used to differentiate between physiological and pathological intraprostatic tracer uptake

High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial

INTRODUCTION: Acute pancreatitis (AP) is an inflammatory disease with no specific treatment. Mitochondrial injury followed by ATP depletion in both acinar and ductal cells is a recently discovered early event in its pathogenesis. Importantly, preclinical research has shown that intracellular ATP delivery restores the physiological function of the cells and protects from cell injury, suggesting that restoration of energy levels in the pancreas is therapeutically beneficial. Despite several high quality experimental observations in this area, no randomised trials have been conducted to date to address the requirements for energy intake in the early phase of AP. METHODS/DESIGN: This is a randomised controlled two-arm double-blind multicentre trial. Patients with AP will be randomly assigned to groups A (30 kcal/kg/day energy administration starting within 24 hours of hospital admission) or B (low energy administration during the first 72 hours of hospital admission). Energy will be delivered by nasoenteric tube feeding with additional intravenous glucose supplementation or total parenteral nutrition if necessary. A combination of multiorgan failure for more than 48 hours and mortality is defined as the primary endpoint, whereas several secondary endpoints such as length of hospitalisation or pain will be determined to elucidate more detailed differences between the groups. The general feasibility, safety and quality checks required for high quality evidence will be adhered to. ETHICS AND DISSEMINATION: The study has been approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (55961-2/2016/EKU). This study will provide evidence as to whether early high energy nutritional support is beneficial in the clinical management of AP. The results of this trial will be published in an open access way and disseminated among medical doctors. TRIAL REGISTRATION: The trial has been registered at the ISRCTN (ISRTCN 63827758)